Cargando…

Therapeutic effect of palbociclib in chondrosarcoma: implication of cyclin-dependent kinase 4 as a potential target

BACKGROUND: Chondrosarcoma is a malignant cartilaginous neoplasm of the bone which resistant to radiation therapy and chemotherapy. Cyclin-dependent kinase 4 (CKD4) is highly expressed in human cancer, and palbociclib, the inhibitor of CDK4 has been used clinically under FDA approval for application...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ouyang, Zhengxiao, Wang, Sisi, Zeng, Ming, Li, Zhihong, Zhang, Qing, Wang, Wanchun, Liu, Tang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390580/ https://www.ncbi.nlm.nih.gov/pubmed/30808351 http://dx.doi.org/10.1186/s12964-019-0327-5

Ejemplares similares

Correction: therapeutic effect of palbociclib in chondrosarcoma: implication of cyclin-dependent kinase 4 as a potential target
por: Ouyang, Zhengxiao, et al.
Publicado: (2023)

Targeting Cyclin-Dependent Kinases in Synovial Sarcoma: Palbociclib as a Potential Treatment for Synovial Sarcoma Patients
por: Vlenterie, Myrella, et al.
Publicado: (2016)

Phase I study of palbociclib, a cyclin‐dependent kinase 4/6 inhibitor, in Japanese patients
por: Tamura, Kenji, et al.
Publicado: (2016)

Biological Effects of Cyclin-Dependent Kinase Inhibitors Ribociclib, Palbociclib and Abemaciclib on Breast Cancer Bone Microenvironment
por: Iuliani, Michele, et al.
Publicado: (2022)

Palbociclib can overcome mutations in cyclin dependent kinase 6 that break hydrogen bonds between the drug and the protein
por: Hernandez Maganhi, Stella, et al.
Publicado: (2017)

Therapeutic targeting of transcriptional cyclin-dependent kinases
por: Galbraith, Matthew D., et al.
Publicado: (2018)

Inhibiting Cyclin-Dependent Kinase 6 by Taurine: Implications in Anticancer Therapeutics
por: Yousuf, Mohd, et al.
Publicado: (2022)

Cyclin-Dependent Kinase 4/6 Inhibitor (Palbociclib) Induced Aplastic Anemia in a Patient with Metastatic Breast Cancer
por: Nwabudike, Stanley Madu, et al.
Publicado: (2018)

The Resistance of Cancer Cells to Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, is Mediated by the ABCB1 Transporter
por: Fu, Han, et al.
Publicado: (2022)

Integrated genomic analyses in PDX model reveal a cyclin-dependent kinase inhibitor Palbociclib as a novel candidate drug for nasopharyngeal carcinoma
por: Hsu, Cheng-Lung, et al.
Publicado: (2018)

Vitiligo-like lesions induced by cyclin-dependent kinase 4/6 inhibitor Palbociclib: a case report and literature review
por: Gao, Shan, et al.
Publicado: (2023)

Safety and efficacy profile of cyclin‐dependent kinases 4/6 inhibitor palbociclib in cancer therapy: A meta‐analysis of clinical trials
por: Guo, Linghong, et al.
Publicado: (2019)

Cyclin-dependent Kinase 4/6 Inhibitor Palbociclib in Combination with Ralaniten Analogs for the Treatment of Androgen Receptor–positive Prostate and Breast Cancers
por: Tien, Amy H., et al.
Publicado: (2022)

Transcription associated cyclin-dependent kinases as therapeutic targets for prostate cancer
por: Constantin, Theodora A., et al.
Publicado: (2022)

Cyclin-dependent kinases
por: Malumbres, Marcos
Publicado: (2014)

Targeting cyclin-dependent kinase 4/6 as a therapeutic approach for mucosal melanoma
por: Shi, Chao-ji, et al.
Publicado: (2021)

Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib
por: Bagegni, Nusayba, et al.
Publicado: (2017)

Cyclin-dependent kinase 7 is a therapeutic target in high-grade glioma
por: Greenall, S A, et al.
Publicado: (2017)

Synaptic roles of cyclin-dependent kinase 5 & its implications in epilepsy
por: Dixit, Aparna Banerjee, et al.
Publicado: (2017)

Distraction osteogenesis and arthrodesis as a new surgical option for chondrosarcoma in the distal tibia
por: Ouyang, Zhengxiao, et al.
Publicado: (2015)

The non-neuronal cyclin-dependent kinase 5 is a fibrotic mediator potentially implicated in systemic sclerosis and a novel therapeutic target
por: Wei, Jun, et al.
Publicado: (2017)

Cyclin-Dependent Kinase Inhibitors and Their Therapeutic Potential in Colorectal Cancer Treatment
por: Thoma, Oana-Maria, et al.
Publicado: (2021)

Inhibitors, PROTACs and Molecular Glues as Diverse Therapeutic Modalities to Target Cyclin-Dependent Kinase
por: Rana, Sandeep, et al.
Publicado: (2021)

The Regulation of Cyclins and Cyclin-Dependent Kinases in the Development of Gastric Cancer
por: Javed, Aadil, et al.
Publicado: (2023)

Functional Differentiation of Cyclins and Cyclin-Dependent Kinases in Giardia lamblia
por: Kim, Juri, et al.
Publicado: (2023)

Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression
por: Yang, Liu, et al.
Publicado: (2015)

Targeting Cyclin-Dependent Kinases for Treatment of Gynecologic Cancers
por: Lin, Z. Ping, et al.
Publicado: (2018)

Cyclin-dependent kinases in C. elegans
por: Boxem, Mike
Publicado: (2006)

The Renaissance of Cyclin Dependent Kinase Inhibitors
por: Ettl, Tobias, et al.
Publicado: (2022)

Decreased sensitivity of cyclin-dependent kinase 4/6 inhibitors, palbociclib and abemaciclib to canine lymphoma cells with high p16 protein expression and low retinoblastoma protein phosphorylation
por: MAYLINA, Leni, et al.
Publicado: (2022)

Cyclin-dependent kinase control of motile ciliogenesis
por: Vladar, Eszter K, et al.
Publicado: (2018)

Ambra1 modulates the sensitivity of mantle cell lymphoma to palbociclib by regulating cyclin D1
por: Jiang, Zhiping, et al.
Publicado: (2023)

Cyclin-dependent kinase 7 inhibitor THZ1 in cancer therapy
por: Li, Bin-Bin, et al.
Publicado: (2019)

Cyclin-dependent kinase 7 (CDK7) is an emerging prognostic biomarker and therapeutic target in osteosarcoma
por: Ma, Hangzhan, et al.
Publicado: (2021)

Cyclin-Dependent Kinase and Antioxidant Gene Expression in Cancers with Poor Therapeutic Response
por: Scaria, George S., et al.
Publicado: (2020)

Lysosomal trapping of palbociclib and its functional implications
por: Llanos, Susana, et al.
Publicado: (2019)

Clinical implications and molecular mechanisms of Cyclin-dependent kinases 4 for patients with hepatocellular carcinoma
por: Wei, Zhong-liu, et al.
Publicado: (2022)

Clinical anticancer drug development: targeting the cyclin-dependent kinases
por: Benson, C, et al.
Publicado: (2005)

Targeting cyclin-dependent kinases for the treatment of pulmonary arterial hypertension
por: Weiss, Astrid, et al.
Publicado: (2019)

Targeting Protein-Protein Interactions to Inhibit Cyclin-Dependent Kinases
por: Klein, Mark
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_q3fg1gt6djuhsov42885lt2pnv